Sanofi Ventures: Investment Portfolio & Startup News
Sanofi Ventures
To add a bio or update investment portfolio click update information.
Investment Portfolio


T-Therapeutics closes a £100m Series B led by Advent Life Sciences and British Business Bank to take its cancer and autoimmune treatments into clinical trials
T-Therapeutics is a biotechnology company developing T cell engager treatments based on human T cell receptors. Its drug programmes target cancer and autoimmune diseases.


OMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
OMass Therapeutics is a biotechnology company developing small molecule therapeutics against highly validated target ecosystems in endocrinology and immunology. OMass Therapeutics develops OMS1620 for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome and advances an SLC15A4 inhibitor for lupus and related diseases.


T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
- 2(12 months)
- sanofiventures.com
More venture news
- 17 Nov 2026

Model MLModel ML secures a £190m Series B led by General Atlantic and QED Investors to expand its AI operating system for financial services
Series BFintech - 16 Nov 2026

SubdialSubdial secures a £15m Series B led by Gresham House Ventures to buy and sell pre-owned watches
Series BConsumer - 12 Nov 2026

GriffinGriffin closes a £15m Series B led by Octagon Partners to add cards and stablecoin payments to its banking platform
Series BFintech